Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Galluzzo

Showing results (51-60 of 111) with videos related to

Pageof 12
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug|August 18, 2023
Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With DupilumabVittoria Cioppa, Laura Lazzeri, Andrea Carraro, et al.
Health Science Reports|May 12, 2021
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol?Annunziata Dattola, Elisabetta Botti, Marco Galluzzo, et al.
Molecular Diagnosis & Therapy|January 29, 2017
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort StudyMarina Talamonti, Marco Galluzzo, Arianna Zangrilli, et al.
Dermatology and Therapy|March 13, 2026
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 WeeksEdoardo Mortato, Marina Talamonti, Lorenzo Savastano, et al.
Journal of Clinical Medicine|September 14, 2024
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life ExperienceLorenzo Marcelli, Alfredo Belcastro, Marina Talamonti, et al.
Expert Opinion on Biological Therapy|May 26, 2018
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observationMarco Galluzzo, Marina Talamonti, Clara De Simone, et al.
Dermatology and Therapy|May 29, 2024
A Multidisciplinary Approach Is Beneficial in Atopic DermatitisPaolo Amerio, Silvia Mariel Ferrucci, Marco Galluzzo, et al.
Dermatology Practical & Conceptual|May 29, 2024
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian CohortGiacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, et al.
Medicine|January 26, 2019
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional studyMaria Sole Chimenti, Giulia Lavinia Fonti, Paola Conigliaro, et al.
Dermatology (Basel, Switzerland)|December 19, 2015
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in PsoriasisMarco Galluzzo, Andreea Nicoleta Boca, Elisabetta Botti, et al.
Pageof 12

Showing results (51-60 of 111) with videos related to

Sort By:
Pageof 12
Dermatitis : Contact, Atopic, Occupational, Drug|August 18, 2023
Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With DupilumabVittoria Cioppa, Laura Lazzeri, Andrea Carraro, et al.
Health Science Reports|May 12, 2021
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol?Annunziata Dattola, Elisabetta Botti, Marco Galluzzo, et al.
Molecular Diagnosis & Therapy|January 29, 2017
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort StudyMarina Talamonti, Marco Galluzzo, Arianna Zangrilli, et al.
Dermatology and Therapy|March 13, 2026
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 WeeksEdoardo Mortato, Marina Talamonti, Lorenzo Savastano, et al.
Journal of Clinical Medicine|September 14, 2024
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life ExperienceLorenzo Marcelli, Alfredo Belcastro, Marina Talamonti, et al.
Expert Opinion on Biological Therapy|May 26, 2018
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observationMarco Galluzzo, Marina Talamonti, Clara De Simone, et al.
Dermatology and Therapy|May 29, 2024
A Multidisciplinary Approach Is Beneficial in Atopic DermatitisPaolo Amerio, Silvia Mariel Ferrucci, Marco Galluzzo, et al.
Dermatology Practical & Conceptual|May 29, 2024
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian CohortGiacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, et al.
Medicine|January 26, 2019
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional studyMaria Sole Chimenti, Giulia Lavinia Fonti, Paola Conigliaro, et al.
Dermatology (Basel, Switzerland)|December 19, 2015
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in PsoriasisMarco Galluzzo, Andreea Nicoleta Boca, Elisabetta Botti, et al.
Pageof 12